For this phase 2 , single-center , double-blind , parallel , placebo-controlled trial ( ClinicalTrials.gov identifier NCT01096082 ) , 62 patients who had MJD/SCA3 with a disease duration 10 years and an independent gait were randomly assigned ( 1:1 ) to receive either lithium or placebo .